Get 250+ investors tailored to your startup

Invest in your industry and stage
Emails & contact info included
Excel and CSV export
Automatically

Trusted by 3,000+ startups

Top 50 Life Science VC (Venture Capital) Funds in United States in January 2026

Last updated: Jan 2026 A list of 50 VC (Venture Capital) funds that invest in Life science startups based in United states. We rank investors based on the number of investments they made in Life science companies from United states. We update this investor list every month.

Top 50 Life Science VC (Venture Capital) Funds in United States in January 2026

Investor	Life Science United States investments
ARCH Venture Partners	24
SOSV	21
Alexandria Venture Investments	21
Northpond Ventures	19
RA Capital Management	15
Novartis Venture Fund	14
DCVC	13
Third Rock Ventures	13
Atlas Venture	13
Civilization Ventures	12
Alix Ventures	12
8VC	12
OrbiMed	12
Andreessen Horowitz	11
Fifty Years	11
Hatteras Venture Partners	11
Artis Ventures	11
KdT Ventures	10
MPM Capital	10
Sahsen Ventures	10
Google Ventures	9
Longwood Fund	9
Flagship Pioneering	9
Rev1 Ventures	9
Pear VC	8
5AM Ventures	8
SR One	8
Playground Global	8
Vivo Capital	8
Cormorant Asset Management	8
iSelect Fund	8
The Column Group	8
Apple Tree Partners	8
New Enterprise Associates	8
Lux Capital	8
Versant Ventures	8
Roche Venture Fund	7
Oreilly AlphaTech Ventures	7
Breakout Ventures	7
Alumni Ventures	7
Horizons Ventures	7
Dolby Family Ventures	7
Takeda Ventures	7
Connecticut Innovations	7
Khosla Ventures	7
Foresite Capital	7
Mission BioCapital	7
Illumina Ventures	7
Omega Funds	7
Digitalis Ventures	7

Find investors that fund startups like yours. Automatically.

Our algorithm will find investors that invest in your industry, stage, and geography.

Investor list

ARCH Venture Partners provides seed / early stage venture capital for technology firms in information technology, life sciences, and physical sciences

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, China, United Kingdom

Portfolio highlights

Paradigm — Paradigm is building a platform that enables equitable access to clinical trials while enhancing efficiency and improving ease of use for providers.
Basking Biosciences — Basking Biosciences is a startup that’s developing a therapy to restore blood flow to the brain during ischemic stroke, preventing hemorrhage and long-term damage.
Soufflé Therapeutics — Soufflé Therapeutics is a biotechnology company specializing in the development of nucleic acid medicines designed for precise delivery and targeting of disease-causing cells. The company's mission is to create potent, precise, and safe medicines that can be tailored for a broad range of diseases by leveraging breakthroughs in genetic medicineand drug delivery technology.

SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.

Investment focus

Biotechnology, Health Care, Software
Seed, Convertible Note, Pre-Seed
United States, India, United Kingdom

Portfolio highlights

MixRift — MIXRIFT - game developers specialized in Mixed Reality
unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.

Alexandria Venture Investments is a venture capital firm that develops work in real estate technology, and healthcare sectors. The company's strategic venture capital platform is Alexandria Venture Investments. Since its inception in 1996, the company has invested in disruptive life science, agrifood tech, and technology companies that aredeveloping transformative new modalities and platforms to meaningfully improve human health.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, Canada, France

Portfolio highlights

Tr1x — Tr1x develops cellular therapies intended for the treatment of autoimmune disorders.
Affinia Therapeutics — Affinia Therapeutics is expanding what's possible in adeno-associated virus (AAV) gene therapy today and bringing transformative medicines for people.
Accipiter Biosciences — Accipiter Biosciences is a biotechnology company.

Northpond Ventures is a science-driven venture capital ﬁrm headquartered in Bethesda, Maryland. Our mission is to build a better tomorrow. Our investments are focused on life sciences, technology, and aﬃliated industries.

Investment focus

Biotechnology, Health Care, Life Science
Series A, Series B, Series C
United States, United Kingdom, Canada

Portfolio highlights

Vizgen — The next generation of genomics, expanding the impact of spatial context and demonstrating the potential of in situ single-cell spatial genomics.
Octave — Octave Bioscience is an early-stage molecular diagnostics company focused on neurodegenerative diseases and conditions. The company was co-founded by Melinda Thomas and William Hagstrom in 2013. Octave Bioscience is headquartered in Menlo Park, California, United States.
Elephas — Elephas is a live tumor imaging company developing novel cancer diagnostic solutions to predict treatment outcomes and accelerate drug development.

RA Capital Management is an investment advisor based in Boston specializing in the life-sciences and drug development sectors. The company's team has been investing since 2002 and is comprised of professionals with training in biology, chemistry, and medicine and also has industry and business development experience at the executive and boardlevels. The company invests in companies with promising technologies and products.

Investment focus

Biotechnology, Health Care, Therapeutics
Series B, Series C, Post-IPO Equity
United States, United Kingdom, Canada

Portfolio highlights

Star Therapeutics — Star Therapeutics mission is to develop therapies for as many diseases as possible for millions of patients.
Triana Biomedicines — Triana Biomedicines is building the leading molecular glue discovery platform to regulate disease targets that are difficult to address with any other modality. Triana’s drug discovery engine is powered by high- resolution structural insights, state-of-the-art in silico tools, and bespoke chemical libraries. The research team has validated thebest-in-class platform and initiated multiple programs across different disease areas.
Alchemab Therapeutics — Alchemab Therapeutics is developing natural protective antibodies designed to keep people free of hard-to-treat diseases. They are building their transformative engine to identify novel drug targets and develop a broad pipeline of novel antibody therapeutics for hard-to-treat cancers, neurodegenerative conditions, and infectious diseases.

Learn about the approach the Novartis Venture Fund takes to investing in innovative life science companies developing biotechnology and biopharmaceutical therapeutics that address unmet patient needs.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, Switzerland, United Kingdom

Portfolio highlights

Rhygaze — Rhygaze develops a novel gene therapy that targets cone cells to restore vision in patients suffering from diseases causing blindness.
Granite Bio — Targeting fundamentals of Inflammation, Autoimmunity and Fibrosis. Granite Bio develops first-in-class therapeutic antibodies depleting pathogenic cells with the potential to transform inflammatory and fibrotic diseases.
Atalanta Therapeutics — Atalanta was created to address the urgent global need for interventions to treat neurodegenerative diseases.

We are deep tech venture capital.

Investment focus

Software, Artificial Intelligence, Machine Learning
Seed, Series A, Series B
United States, Canada, United Kingdom

Portfolio highlights

OraLiva — OraLiva is a lean startup focused to turning medical breakthroughs into real-world applications.
Radiant — Clean. Portable. Safe. Energy
Shennon Biotechnologies — Shennon Biotechnologies analyzes and manipulates a massive number of cells on the single-cell level to develop more effective treatments for human diseases. It functionally profiles millions of immune cells to find the best targets for cancer immunotherapy.

Third Rock Ventures invests in transformational life science companies that show high growth potential and are well-positioned to make a difference in the marketplace. Third Rock Ventures believes in the companies we start and makes significant initial investments, which are frequently supplemented by strategic collaborations, to help our firmsprogress in life-changing medicines, technologies, and diagnostics.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States

Portfolio highlights

Trace Neuroscience — Trace Neuroscience is a biopharmaceutical company that aims to extend the promise of genetic medicine to patients with neurodegenerative illnesses.
Jounce Therapeutics — Concentra is a biosciences company.
Seaport Therapeutics — Seaport Therapeutics operates as a clinical stage biopharmaceutical company.

Atlas Venture is an early-stage venture capital firm that creates and invests in biotech startup companies led by promising entrepreneurs focusing on life sciences innovation. Its seed-led venture creation strategy rigorously selects and focuses investment on compelling opportunities to build scalable businesses and realize value.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, United Kingdom, Canada

Portfolio highlights

Nimbus Therapeutics — Nimbus Discovery is now Nimbus Therapeutics to reflect our transition into a clinical stage company. Nimbus Therapeutics is a biotechnology company headquartered in Cambridge, Mass., that is pioneering a new computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinicaldevelopment. We are designing highly selective and potent medicines to disrupt known drivers of serious diseases, including metabolic disease, cancer and immune-inflammatory disorders.
Sionna Therapeutics — Sionna Therapeutics is developing novel small molecule therapies to treat cystic fibrosis (CF).
Matchpoint Therapeutics — Matchpoint aims to discover and develop precision small molecules that harness the power of covalency to bring new possibilities to the treatment of serious immune disease and cancer.

DIGITAL HEALTH / AI DIGITAL HEALTH / AI GENE / CELL THERAPIES NASDAQ: RCKT GENE / CELL THERAPIES NASDAQ: RCKT GENOMICS / DIAGNOSTICS GENOMICS / DIAGNOSTICS SYNTHETIC

Investment focus

Biotechnology, Health Care, Medical
Seed, Series A, Series B
United States, United Kingdom, Brazil

Portfolio highlights

Wyndly — Retrain your allergies through sublingual (under-the-tongue) treatment plans. Virtual appointments. Treatment delivered. Get started after your first consult with a board-certified doctor for $49.99.
Trial Library — At Trial Library, we partner with the oncology community to enable the discoverability of clinical trials for anyone, anywhere.
Foresight Diagnostics — We develop innovative diagnostics to advance decision-making in oncology drug development and patient care.

Supporting early stage Life Science startups driving patient impact. Born from our collective experience as founders, we set out to build the fund we wanted to raise from....

Investment focus

Biotechnology, Health Care, Life Science
Seed, Series A, Pre-Seed
United States

Portfolio highlights

Elegen — Skip cloning with the only entirely cell-free DNA synthesis provider. Sequences up to 7 kb. Error rates as low as 1:70,000/bp. Manufactured in USA, NGS-verified and shipped globally in as few business days. .
iOrganBio — iOrganBio is a pioneering cell production platform that uses CellForge to facilitate the intelligent manufacturing of human cells and organoids.
Galatea Bio — Galatea Bio, a US-based biotechnology company was founder by Carlos Bustamante, Nicholas Katsanis and Alexander Ioannidis. Our mission is to drive groundbreaking discoveries in healthcare by pairing genetic diversity with cutting-edge data analytics. Our passion is fueled by a focus on populations historically underrepresented in genetics research.We achieve this by leveraging our world-class clinical network and biobank, cutting-edge algorithms, and innovative analyses to discover and validate new tests, treatments, and cures that will improve the lives of all.

8VC is a technology and life sciences investment firm that partners with founders to develop transformational technologies. The firm focuses on creating long-term economic and societal value through its investments across various sectors, including healthcare and logistics.

Investment focus

Software, Health Care, Artificial Intelligence
Series A, Seed, Series B
United States, United Kingdom, Canada

Portfolio highlights

Ritten — Ritten delivers a platform that helps clinicians and administrators provide personalized, data-informed care. The company's platform offers customized workflow configurations that help to deliver complex treatment consistently and compliantly, enabling clinicians and administrators to maintain a comprehensive patient record that tracks allaspects of a patient's care, including clinical notes, medications, and treatment plans, and deliver personalized, data-informed care.
ClearFeed — Conversational Support Platform on Slack
Citizen Health — Accelerate access to better treatments today, and create cures for tomorrow.

Leading Global Healthcare Platform with Deep Proprietary Resources and Global Industry Coverage.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series A, Series C
United States, China, Israel

Portfolio highlights

TandemAI — Streamline discovery with our integrated drug discovery platform, blending AI, physics-based tools, and wet lab for unparalleled innovation. Click now.
Epigenic Therapeutics — Epigenic Therapeutics is a biotech firm that offers gene editing therapy.
Pionyr Immunotherapeutics — Pionyr Immunotherapeutics is developing cancer immunotherapies that target the tumor microenvironment to enhance the body’s antitumor immunity. The company is exploiting novel target discovery and antibody generation platform technologies to create the next generation of immuno-oncology therapeutics. The company’s approach, Myeloid Tuning™, isdesigned to enhance the immune system’s anti-tumor response by altering the cellular infiltrate of the tumor microenvironment with high specificity.

Andreessen Horowitz (a16z) is a venture capital firm in Silicon Valley, California, investing in bold founders, innovators, and entrepreneurs building the future through technology.

Investment focus

Software, Information Technology, Internet
Series A, Seed, Series B
United States, United Kingdom, Brazil

Portfolio highlights

Granular — Corteva Agriscience software and digital solutions give the real-time, field-by-field information needed to maximize yield & manage input costs.
Databricks — Databricks offers a unified platform for data, analytics and AI. Build better AI with a data-centric approach. Simplify ETL, data warehousing, governance and AI on the Data Intelligence Platform.
Odyssey — Odyssey connects families with states to get access to funding from states to use with approved vendors to customize education for children who need it most.

WE BACK HEROES using technology to solve the world's biggest problems

Investment focus

Biotechnology, Health Care, Medical
Seed, Series A, Series B
United States, Germany, Canada

Portfolio highlights

Farcast — Unlocking satellite internet capacity through user terminal innovation
Solugen — Solugen's mission is to decarbonize the chemicals industry. Solugen combines synthetic biology with metal catalysis to make carbon negative chemicals at scale.Solugen's patented approach takes advantage of bio-inspired reactions to use plant material as a low-cost feedstock to produce novel products cost-competitive with thecompetition.
Valence Discovery — Empowering drug discovery scientists with the latest advances in AI-enabled drug design

Hatteras Venture Partners is a venture capital firm based in Research Triangle Park, NC, with a focus on biopharmaceuticals, medical devices, diagnostics, and related opportunities in human medicine. Founded in 2000, the firm consists of an experienced team with a broad and complementary skill set that is particularly relevant to buildingsuccessful new biomedical companies. The Hatteras Venture Partners team brings operational experience, a successful track record, and a proven ability to enhance the value of the companies in which it invests. With three funds, the firm has more than $120 million under management.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
United States, Canada

Portfolio highlights

iRiva Medical — iRiva Medical is developing novel neuromodulation therapies to address unmet therapeutic requirements in large patient populations.
Viamet Pharmaceuticals — Viamet Pharmaceuticals discovers and develops "best-in-class" inhibitors of validated metalloenzymes via an innovative and proprietary metal-binding approach, their Metallophileâ„¢ Technology. Viamet's disruptive Metallophileâ„¢ technology is based on their world-class expertise in bioinorganic chemistry and metalloenzymes and allowsthem to identify validated targets with high therapeutic and commercial potential; leverage existing metalloenzyme inhibitors as the basis for Viamet's best-in-class analogs; and rapidly and cost-effectively generate best-in-class, patentable, small molecule compounds by optimizing the metal-binding component of existing inhibitors.
TetraLogic Pharmaceuticals — TetraLogic Pharmaceuticals is a privately held biopharmaceutical company that discovers and develops small molecule drugs that modulate programmed cell death pathways to treat debilitating diseases and conditions. The company's Smac Mimetics neutralize critical blocks in the apoptosis pathway to selectively destroy cancer cells. ItsNecrostatin drugs block critical steps in the process leading to necrosis, enabling cell survival in a wide range of diseases and injuries where necrosis is a critical component of pathology.

Artis Ventures has spent over a decade backing bold teams who take the hard path, building market-defining companies to re-shape, re-invent, and re-make industries.

Investment focus

Biotechnology, Health Care, Software
Series A, Series B, Seed
United States, India, Germany

Portfolio highlights

Freenome — Freenome is a biotechnology company based in South San Francisco that has pioneered the most comprehensive multiomics platform for early cancer detection with a simple blood test.
Activ Surgical — Activ Surgical provides Intraoperative Surgical Intelligence aimed at transforming healthcare standards and reducing complication rates.
Affect — Get addiction and mental health treatment through an app that offers a full outpatient program, complete with medications and therapy.

KdT Ventures is the standard for early-stage frontier science investing.

Investment focus

Biotechnology, Health Care, Medical
Seed, Series A, Series B
United States, Israel, Germany

Portfolio highlights

Zag Bio — Zag Bio is harnessing the immune system in a whole new way by targeting the thymus to change treatment possibilities for millions of patients with autoimmune diseases.
PHNX Materials — PHNX Materials is a manufacturing company that specializes in turning waste into essential materials and reduce carbon emissions.
Faeth Therapeutics — Home | Faeth

Powering Breakthroughs in Life Sciences

Investment focus

Biotechnology, Health Care, Pharmaceutical
Series A, Series B, Series C
United States, Canada, United Kingdom

Portfolio highlights

Syndax Pharmaceuticals — Syndax Pharmaceuticals is a clinical-stage pharmaceutical company that focuses on an HDAC inhibitor for solid tumors and hematological tumors. It offers therapies to treat solid tumors and lung, breast, and hematological cancer. The company is developing axatilimab, a monoclonal antibody that blocks the colony-stimulating factor 1 (CSF-1) receptor,in development for chronic Graft versus Host Disease, and entinostat, a class I HDAC inhibitor.Syndax Pharmaceuticals pipeline includes and SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, in development for the treatment of patients with MLLr and NPM1 acute leukemias.
Portola Pharmaceuticals — As Alexion, AstraZeneca Rare Disease, we are delivering life-changing therapies to people living with rare diseases.
Rhythm Pharmaceuticals — Rhythm Pharmaceuticals is a global biopharmaceutical company committed to transforming the lives of patients with rare neuroendocrine diseases by rapidly advancing care and precision medicines that address the root cause.

Sahsen Ventures is a venture capital firm making investments in for-profit and nonprofit organizations with an emphasis on technology and biotechnology. It was established in 2016 and is based in Seattle, Washington.

Investment focus

Biotechnology, Health Care, Non Profit
Funding Round, Series A, Seed
United States, China, Ghana

Portfolio highlights

Insamo — Insamo is a global biotechnology company pioneering the discovery of membrane-permeable and orally available cyclic-peptides with antibody-like binding affinity.
Outpace Bio — Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety.It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacyand safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.
Archon Biosciences — Archon is a biotechnology firm that creates computationally engineered proteins to unleash potent therapeutic targets beyond the grasp of current methods and improve disease management.

GV supports innovative founders moving the world forward.

Investment focus

Software, Health Care, Biotechnology
Series A, Series B, Seed
United States, United Kingdom, Switzerland

Portfolio highlights

Instawork — Instawork connects local businesses with proven hourly workers for temp, temp-to-hire shift work.
SingleStore — SingleStore is a provider of a database for operational analytics and cloud-native applications. It provides global enterprises with an intelligent database that works on any cloud on-premises or as a service runs transactions and analytics at the same time and lets clients promote their business through analytics and combine semi-structured datainto a consolidated big data platform.
Resistant AI — Resistant AI provides fraud detection and prevention in automated document processing workflows, transaction monitoring, and identities analysis.

Longwood creates and invests in science-based companies that develop novel solutions for important medical problems

Investment focus

Biotechnology, Therapeutics, Health Care
Series A, Series B, Series C
United States, United Kingdom, Italy

Portfolio highlights

Pulmocide — Pulmocide is developing novel inhaled medicines for serious respiratory diseases
Newleos Therapeutics — Newleos Therapeutics is a biotech startup dedicated to producing safer and more effective neuroscience medicines.
Vertero — Axial Therapeutics is a biotechnology company fundamentally changing the treatment of neurological diseases and disorders by harnessing groundbreaking science in the microbiome-gut-brain axis.

We create breakthroughs in human health and sustainability and build bioplatform companies . Companies founded

Investment focus

Biotechnology, Health Care, Medical
Series B, Series C, Series A
United States, Canada, United Kingdom

Portfolio highlights

Lila Sciences — Lila Sciences is a platform that uses artificial intelligence to support research in life sciences, chemical sciences, and materials sciences. It develops AI-driven tools and autonomous labs to improve research efficiency and facilitate scientific discoveries. The platform is designed to enhance various aspects of the scientific method andcontribute to advancements in technology and innovation.
Terrana Biosciences — Terrana's innovative technological platform enables resilient agriculture in a fast changing world by providing RNA-based plant health solutions.
Expedition Medicines — Defining a new era in drug discovery where chemistry rewrites the rules of biology to engage any protein target.

Rev1 Ventures provides seed stage venture capital funding in Columbus, Ohio along with startup services, space, mentoring, and connections. Learn more!

Investment focus

Software, Health Care, Information Technology
Seed, Series A, Funding Round
United States, Germany

Portfolio highlights

RedNOx — Cutting-edge sensor technology for emissions reduction in transportation and agriculture.
SureImpact — SureImpact is a user-friendly, social services case management software that helps you track and report outcomes, measure participant needs, and demonstrate impact to funders.
HealthPlan Data Solutions — The HDS technology platform offers multiple solutions to help key stakeholders across the pharmacy spectrum ensure every claim adheres to the PBM contract and plan design, delivering more effective pharmacy benefit cost management.

Pear VC partners with entrepreneurs from day zero to build category-defining companies.

Investment focus

Software, Artificial Intelligence, Health Care
Seed, Series A, Pre-Seed
United States, Brazil, Colombia

Portfolio highlights

Axle Health — Axle Health provides scheduling and workforce management software to help home healthcare and hospice providers improve their clinician productivity.
Flicker Corp. — Multi-agent AI system that finds and fixes vulnerabilities faster than ever before.
Nightfall — Nightfall is one trusted DLP platform to discover, classify, and protect sensitive data across SaaS and cloud apps with machine learning.

5AM Ventures is a venture capital firm that offers seed- and early-stage investments to its clients. The company’s client portfolio consists of firms in the biopharmaceutical, life sciences, medical technology, and research instrument industries. 5AM Ventures was founded in 2002 by John Diekman and Andrew Schwab and is based in California.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, Switzerland, United Kingdom

Portfolio highlights

Fellow Health — Fellow provides peer-reviewed, clinically valid, mail-in semen analysis for clinics looking for improved compliance and a patient-friendly solution to fertility testing.
Renasant Bio — Renasant Bio is a biopharmaceutical company pioneering disease-modifying oral small molecule treatments.
CAMP4 Therapeutics — CAMP4 is focused on addressing the fundamental cause of disease by controlling the output of genes central to disease. By taking advantage of the gene circuitry code, CAMP4 is able to control gene production through signaling pathways the cell is already utilizing to regulate gene expression. Their predictions enables CAMP4 to have a rapid start todisease treatment, significantly reducing the time and risk to bring new medicines to patients.

SR One Capital Management is a leading trans-Atlantic biotech venture capital firm that partners with top entrepreneurs, scientists and investment partners to seek to build elite biotechnology companies. Our mission is to translate ground-breaking technologies into next generation medicines to benef

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, United Kingdom, Canada

Portfolio highlights

MiroBio — MiroBio's platform is based on ground-breaking research by their scientific founders at the University of Oxford delineating how immune cells communicate and how they are activated. These insights have enabled MiroBio to create antibodies that can leverage natural signalling mechanisms to restore immune system balance and control.
Bicycle Therapeutics — Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need.The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.
MISSION Therapeutics — Deubiquitylating enzymes: multiple drug opportunities across therapeutic areas

Playground Global is an early-stage venture capital firm backing technical and scientific founders with deep engineering expertise, a collaborative environment, and a first-hand understanding of the intricacies of deep tech. Established in 2015 and headquartered in Palo Alto, CA, Playground’s mission is to transform ambitious ideas into impactfulbusinesses that benefit humanity and the planet. We invest in areas that span across next gen compute automation, energy transition and engineered biology. Playground has been an early – and frequently first investor – in companies that include PsiQuantum, Relativity Space, Ultima Genomics, MosaicML (acq. by Databricks), d-Matrix, and Strand Therapeutics.

Investment focus

Software, Robotics, Biotechnology
Series A, Seed, Series B
United States, Canada, Italy

Portfolio highlights

Ayar Labs — Ayar Labs solves bandwidth and power bottlenecks by moving data using light. We built the world's first optical I/O chiplets.
Saltbox — Saltbox makes the hardest parts of running an ecommerce business simple. Explore our logistics and warehouse solutions growing eCommerce companies
Sizable energy — Sizable Energy addresses the critical need for secure, affordable, and sustainable energy storage. Sizable Energy patented technology and straightforward design extends pumped hydro deployment to any offshore location with a depth of at least a few hundred meters. By leveraging a novel, modular, and easily deployable method, we utilize thegravitational potential of a solution 20% heavier than seawater, like saturated sea salt brine, within seawater.

The firm is a 25-year-old global investment firm focused on healthcare with approximately $5.8 billion in AUM, which we have invested in over 290 public and private companies worldwide. Headquartered in Palo Alto, California, with offices in Asia. Our team consists of 50 multi-disciplinary professionals, including, physicians, scientists,entrepreneurs, operating executives, and industry experts. The firm operates as a multi-fund investment platform, covering growth equity, private equity including buyout, venture capital, and public equity. Vivo invests broadly in healthcare across all fund strategies, including biotechnology, pharmaceuticals, medical devices, and healthcare services, with a focus on the largest healthcare markets.

Investment focus

Biotechnology, Health Care, Pharmaceutical
Series B, Series C, Post-IPO Equity
United States, China, United Kingdom

Portfolio highlights

CAMP4 Therapeutics — CAMP4 is focused on addressing the fundamental cause of disease by controlling the output of genes central to disease. By taking advantage of the gene circuitry code, CAMP4 is able to control gene production through signaling pathways the cell is already utilizing to regulate gene expression. Their predictions enables CAMP4 to have a rapid start todisease treatment, significantly reducing the time and risk to bring new medicines to patients.
Trevi Therapeutics — Trevi Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Trevi is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF), andlevodopa-induced dyskinesia (LID) in patients with Parkinson’s disease. These conditions share common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems. Trevi is currently conducting a Phase 2b/3 clinical trial of nalbuphine ER, referred to as the PRISM trial, in patients with severe pruritus associated with prurigo nodularis.
Chentai New Materials — Chentai New Materials integrates the R&D, design, manufacturing, and sales of high-performance composite ceramics. It Specializes in the innovation and creation of medical high-performance ceramic products.

Cormorant Asset Management is an employee-owned hedge fund sponsor that provides its services to pooled investment vehicles. The firm also focuses on both public and private market innovative companies in the biotechnology and life sciences marketplace.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series A, Series C
United States, China, Switzerland

Portfolio highlights

Numab — Numab Therapeutics AG
Neurona Therapeutics — Neurona Therapeutics is a pre-clinical stage biotechnology company that was founded by four neuroscientists and stem cell pioneers at The University of California, San Francisco. They are focused on the discovery and development of cell-based therapies to treat intractable neurological disease. Its initial aim is to generate therapeuticcompositions of a specific type of nerve cell (or neuron) for targeted delivery into the injured nervous system. Based on nearly two decades of research, they believe that particular subpopulations of neurons have the unique ability to integrate and repair dysregulated neural circuits. Its talented team of scientists, scientific advisors, and board directors is working to accelerate breakthrough treatments for patients with significant unmet medical needs.
Edgewise Therapeutics — See how we bring our unique expertise and singular focus on muscle science to develop novel therapeutics for serious skeletal and cardiac muscle diseases.

Venture investing in Food, Health, and AgTech. A generational investment thesis. Food is Health is longevity

Investment focus

Biotechnology, Health Care, Software
Seed, Series A, Funding Round
United States, Australia, New Zealand

Portfolio highlights

Geltor — The leader in biotech-powered proteins for beauty and wellness, including vegan collagen, elastin, and more, purposefully biodesigned for performance.
Mercy BioAnalytics — We are making early stage cancer 100,000x easier to find using extracellular vesicles found in blood, specific to their parent cells.
Growers Edge — Growers Edge leverages data science to build grower-relevant risk management solutions to meet ever-changing agricultural demands.

The Column Group (TCG) is a venture ecosystem dedicated to fueling scientific innovation in the life sciences industry.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States

Portfolio highlights

Synthekine — Discovering, Developing and Commercializing the Next Generation of Selective Cytokine Therapeutics. We believe that cytokine therapeutics engineered to be selective can fundamentally change the treatment paradigm of cancer and inflammatory disease.
Atavistik Bio — Atavistik Bio is harnessing the power of protein-metabolite interactions to add a new lens to drug discovery.
Gritstone bio — Gritstone Oncology is a clinical-stage biotech company developing tumor-specific cancer immunotherapies to fight multiple cancer types. Its approach seeks to generate a therapeutic immune response by leveraging insights into the immune system’s ability to recognize and destroy tumor cells by targeting tumor-specific neoantigens. GritstoneOncology is headquartered in Emeryville, California, with key functions located in Cambridge, Massachusetts, and Pleasanton, California. It was founded in August 2015 and is listed on the Nasdaq Global Select Market under the ticker symbol GRTS.

ATP, a global leader in life sciences venture capital, is developing the next generation of transformative biotechnology companies. ATP creates science-based companies starting with assets at various stages: from working with scientists on pre-IP ideas, to spinouts from existing company pipelines. The firm provides flexible capital, strategicinsight, and operational resources to build sustainable, research-driven enterprises. ATP invests in its portfolio companies from seed stage through IPO and beyond and supports their management teams in strategic transactions and synergistic business combinations.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Seed
United States, Canada, United Kingdom

Portfolio highlights

Adendra Therapeutics — Adendra is an emerging biotechnology company building on new insights into dendritic cell biology to discover and develop new small molecule and biologic medicines for the treatment of a wide range of cancers and autoimmune diseases.
Red Queen Therapeutics — Staying ahead of viral threats with new innovations in antiviral therapy
Deep Apple Therapeutics — Deep Apple Therapeutics is discovering new small-molecule therapeutics with unprecedented speed and exceptional acumen.

Foundational partners to ambitious founders at every stage of company-building.

Investment focus

Software, Health Care, Biotechnology
Series A, Series B, Series C
United States, India, United Kingdom

Portfolio highlights

Wizard — Join the world's leading businesses using Wizard to sell, market, and engage their customers via text.
Immunomedics — Immunomedics is a biopharmaceutical company that specializes in developing monoclonal antibody-based products for the treatment of cancer and other serious diseases. Its corporate objective is to become a fully-integrated biopharmaceutical company. The company was founded in 1982 and headquartered in Morris Plains, New Jersey.
Willow — Willow is a female technology company that develops an in-bra wearable breast pump. Its breast pumps are cordless and spill-proof. It also tracks milk output through a mobile application along with an online portal, enabling mothers to pump anywhere without hassle. The company was founded in 2014 and is headquartered in Mountain View, California.

Lux Capital manages over $5 billion in assets focused on founding, seed, early-stage, and growth investments at the intersection of technology and the sciences. Lux takes an active role in helping entrepreneurs build successful businesses in high-growth sectors. Its investment team has built over 20 companies from scratch. Lux's investmentstrategy ensures portfolio companies are better connected, have a deeper insight, and command industry leadership faster than their competitors.

Investment focus

Software, Health Care, Artificial Intelligence
Series A, Seed, Series B
United States, United Kingdom, Canada

Portfolio highlights

Clarifai — Clarifai is the leading Machine Learning, Computer Vision, NLP Platform. Label, train, deploy models on one AI platform for developers & data scientists.
Mendaera — Mendaera enables all healthcare providers to perform precise and consistent point-of-care interventions. Their platform combines real-time imaging, robotics, and artificial intelligence to aid physicians in image acquisition and interpretation.
Primer — At Primer, we help organizations make the best use of their investment in data, by using best-in-class machine learning and natural language processing technologies.

Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
United States, Switzerland, Canada

Portfolio highlights

Standard BioTools — Standard BioTools delivers leading genomic and proteomic solutions. Discover CyTOF, Hyperion, and Biomark technologies for deep biological insights.
Rennovia — Rennovia, Inc. produces renewable chemicals. It offers adipic acids and adiponitrile for consumer-end products, including carpets, heat-resistant automotive parts, furniture, apparel, footwear, luggage, adhesives, and coatings. Rennovia was incorporated in 2009 and is based in Menlo Park, California.
Alexza Pharmaceuticals — Alexza Pharmaceuticals is an emerging specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. It was founded in 2001 and headquartered in Mountain View, California.

The Roche Venture Fund is the name given to the corporate venture fund of the healthcare company Roche. Roche has allocated CHF 500 million to invest in and develop commercially successful innovative life science companies. Roche has been investing in early stage companies as part of collaborations since the early-1990s and independent ofcollaborations since 2002. All equity investments made by Roche in biotech and diagnostics companies (including collaboration investments) are negotiated and managed by the Roche Venture Fund. In the past 20 years, the Roche Venture Fund has invested in over 60 companies globally. Currently, Roche Venture Fund has a portfolio of around 30 companies located in 10 countries across Europe, North America and the Pacific Region. The fund is an evergreen fund with CHF 500 million available of which approximately 40% is currently invested.The Roche Venture Fund is a committed long-term stable investor with sufficient money reserved in their fund for follow-on financing rounds. As part of a multinational healthcare company, the Roche Venture Fund has access to considerable expertise both internally and externally. We co-invest with leading venture funds, including other corporate venture funds, on a regular basis.

Investment focus

Biotechnology, Health Care, Therapeutics
Series B, Series A, Series C
United States, United Kingdom, Spain

Portfolio highlights

DiogenX — Welcome to DiogenX. Explore our pioneering research and innovative therapies aimed at transforming diabetes treatment
Mironid — Google Analytics is a web analysis service provided by Google. Google utilizes the data collected to track and examine the use of www.mironid.com, to prepare reports on its activities and share them with other Google services. Google may use the data collected to contextualize and personalize the ads of its own advertising network.
MISSION Therapeutics — Deubiquitylating enzymes: multiple drug opportunities across therapeutic areas

O'Reilly AlphaTech Ventures (OATV) is in the business of funding disruptors, innovators, and hackers of the status quo. From open source to the early days of the web and its recent resurgence, O'Reilly Media has played a key role as trend spotter and advocate for putting world-changing technologies on the map. OATV effort is to bring thelegacy, resources, and relationships of O'Reilly to each investment they make.

Investment focus

Software, E-Commerce, Analytics
Series A, Seed, Series B
United States, United Kingdom, Canada

Portfolio highlights

Pachama — Harnessing AI to drive carbon capture and protect global forests
Paintbrush — Paintbrush provides access to funding for idea-stage founders who are too early for other options.
Impart Security — Real-time API Security spanning discovery, monitoring, and enforcement.

Building the Future Powered by Science

Investment focus

Biotechnology, Life Science, Therapeutics
Seed, Series B, Series A
United States

Portfolio highlights

CytoVale — Cyotvale offers IntelliSep, an FDA-cleared early sepsis detection test powered by the Cytovale System medical device.
Passkey — Passkey Therapeutics is pioneering a new class of medicines, Synergistic Multifunctional Therapeutics (SMThs). It is designed to address complex diseases by targeting rare combinations of proteins that work together.
Copernic Catalysts — Mantel is developing the material solution to carbon capture

Alumni Ventures is a venture capital firm that offers accredited investors access to diversified venture portfolios. The firm operates multiple funds, including alumni-focused and thematic funds, and co-invests alongside established venture firms. Investors can choose between fund-based investing or selecting individual deals. Alumni Venturesleverages a broad network to source capital, evaluate opportunities, and support portfolio companies. The firm manages a portfolio encompassing over 1,400 venture-backed companies across various sectors and stages.

Investment focus

Software, Artificial Intelligence, Information Technology
Seed, Series A, Series B
United States, United Kingdom, Canada

Portfolio highlights

MEDIVIS — Medivis is a leader in AR for healthcare, using augmented reality and artificial intelligence to advance medical imaging and surgical precision.
ZZ Driggs — ZZ Driggs is an award-winning company reimagining how we furnish our lives for a new economy and a more sustainable future. We offer exceptional, sustainable, and ethically-made heirloom-quality furniture to rent, buy, or both, made by the best independent & emerging designers today.
Mythical Games — We are Mythical Games, a Venture-backed next-generation game technology company at the intersection of video games and economics led by industry veterans.

Investing in the deep science and technology that can propel humanity towards a radically better future.

Investment focus

Biotechnology, Artificial Intelligence, Software
Series A, Series B, Seed
United States, United Kingdom, Canada

Portfolio highlights

Keel Labs — AlgiKnit is a collective of designers and scientists who work across disciplines to create new material possibilities. We're creating sustainable, algae-derived, biodegradable yarns and textiles to remediate harmful cycles of fast fashion. Built for performance and cost-competitiveness, AlgiKnit is
Levelset — Construction payment help is here. Find out how Levelset helps thousands of contractors like you resolve problems and streamline payments every day!
Modern Meadow — Discover INNOVERA, Modern Meadow's next-gen biofabricated leather made from plant proteins and recycled rubber. Animal-free, sustainable, and versatile across industries.

Investing in early-stage companies solving the biggest science and engineering challenges since 2014.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Seed, Series B
United States, Austria, Switzerland

Portfolio highlights

Lightform — Lightform LFC Kit and LF2+ AR projector enable you to create light and sound experiences with sound-reactive projection mapping. Lightform brings projection mapping in reach for visual artists, designers, and other creatives.
TripleBlind — TripleBlind unlocks the estimated 105 petabytes of data stored by enterprises today that are inaccessible and not commercialized due to privacy concerns, operational complexity and regulation. The company’s patented breakthroughs in advanced mathematics enable organizations to privately share larger and more diverse data sets. Many high-valueapplications apply, such as innovating enhanced algorithms for medical diagnoses and improving anti-fraud initiatives for financial services. TripleBlind is the only technology that enables enterprises to rapidly commercialize data while maintaining compute performance; enabling all types of analysis on all data types, such as PII, PHI, genomic data, images, and confidential financial records. At the same time, the solution automatically enforces all international and regional data privacy standards including HIPAA, GDPR, PDPA and CCPA.TripleBlind is superior to existing solutions such as homomorphic encryption (slows compute performance), secure enclaves (siloes data), tokenization/masking/hashing and differential privacy (reduces accuracy), synthetic data (not real data), federated learning (limited use for algorithms), confidential computing (requires data centralization) and blockchain (not interoperable). Innovators such as Accenture, the Mayo Clinic and Snowflake trust TripleBlind to protect sensitive data. Please contact us for an overview, live demo or a one-hour, hands-on workshop.
MindImmune Therapeutics — Breaking through barriers to new therapeutics for brain disease.

Takeda Ventures, Inc. (TVI) is the corporate investment arm of Takeda Pharmaceutical Company Limited (TPC). TVI was founded in 2001 and invests in current and future areas of interest for TPC. They are based alongside Takeda’s R&D sites in Cambridge, MA, and San Diego, CA. As a strategic investor, TVI aims to provide support and guidance toentrepreneurs and early-stage companies driving concepts through clinical proof of concept. They also strive to forge active, collaborative interactions that result in synergies with Takeda's considerable R&D resources. Their goal is to build a portfolio of strategic investments, with an immediate emphasis on oncology, gastroenterology, neuroscience, and rare diseases.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Funding Round
United States, United Kingdom, Israel

Portfolio highlights

Be Biopharma — Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.
Degron Therapeutics — Degron Therapeutics is a leading platform company in discovery of molecular glue degraders for cancer treatment.
Accipiter Biosciences — Accipiter Biosciences is a biotechnology company.

At Connecticut Innovations, we see venture capital the way you see your business. Like no one else. We invest in innovative biotech, IT, and other industries.

Investment focus

Health Care, Biotechnology, Software
Seed, Series A, Funding Round
United States, Israel, Canada

Portfolio highlights

Normunity — We create medicines that free normal immunity to defeat cancer using proprietary platforms that uncover novel immuno-oncology mechanisms.
VeraDermics — VeraDermics Inc. is a dermatology pharmaceutical start-up, makers of WartPatch
PHȲND — PHȲND is a subscription-free cloud gaming platform that offers a way to discover, play, and socialize across a wide variety of games.

Khosla Ventures is a venture capital firm that invests in early- to late-stage companies across sectors like AI, healthcare, sustainability, and consumer technology. It manages multiple funds, focusing on startups with innovative technologies or business models. The firm primarily targets sectors like AI, climate tech, digital health, and medtech,offering strategic support to help build long-lasting companies.

Investment focus

Software, Artificial Intelligence, Health Care
Series A, Series B, Seed
United States, India, United Kingdom

Portfolio highlights

Periodic Labs — Periodic Labs develops artificial intelligence systems that simulate and predict the properties of materials using machine learning. The company applies computational models to support the discovery and design of materials used in sectors such as energy, electronics, and infrastructure. It builds tools that aim to reduce the time and costassociated with traditional research and development processes. Periodic Labs uses AI to analyze large-scale scientific data and collaborates with academic and industry partners to support material science research.
Vectra AI — Vectra is the world leader in AI threat detection and response. The Cognito platform uses AI to detect attackers in real time and perform conclusive investigations.
Point One Navigation — Precise Positioning for the next generation of transportation. 10cm accuracy everywhere.

We are a multi-stage investment firm, investing in companies that leverage biology and big data to transform healthcare.

Investment focus

Biotechnology, Health Care, Therapeutics
Series B, Series C, Series A
United States, United Kingdom, Australia

Portfolio highlights

Pharvaris — Pharvaris is a clinical-stage company focused on the discovery and development of novel oral bradykinin B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin B2-receptor-mediated indications.
Indomo — Indomo is developing the first fast-acting at-home solution for inflammatory acne lesions.
Kinnate Biopharma — Kinnate Biopharma is a precision oncology company focused on the design and development of selective small molecules targeting genetic mutations and fusions with no coverage currently.

Mission BioCapital is a life science venture capital firm that invests in early-stage companies. The company leadership team has a long history together, investing in and launching dozens of early-stage life science companies. They are located in regions with a rich concentration of research, discovery, and venture capital investment, and they areknown by leaders of portfolio companies for the expertise and deep support they provide.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Funding Round, Series B
United States, Germany, Switzerland

Portfolio highlights

Sentieon — Sentieon develops a suite of bioinformatics secondary analysis tools that process genomics data with high computing efficiency and fast turnaround time.
Comet Therapeutics — CoEnzyme is a developer of therapies designed to treat orphan neurological disorders. The company develops a treatment to restore dysregulated CoEnzyme A metabolism through its CoEnzyme metabolism platform, enabling physicians to address the profound unmet medical needs.
Jupiter BioVentures — Jupiter BioVentures is a creation engine company that focuses on de-risking early-stage projects.

We invest in companies that are advancing the field of genomics and pioneering new applications in healthcare, agriculture, environmental science, and personal

Investment focus

Biotechnology, Health Care, Life Science
Series A, Series B, Series C
United States, United Kingdom, France

Portfolio highlights

Hepta Bio — The Future Of Diagnostics, Today
Iambic — Iambic has created a cutting-edge AI-driven platform to tackle the most challenging design problems in drug discovery and address unmet patient need.
Infinity Bio — Learn how Infinity Bio's antibody profiling services can detail the reactome in your samples.

We aim to invest in exceptional founders and entrepreneurs and impactful products and platforms across multiple therapeutic areas.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, Switzerland, United Kingdom

Portfolio highlights

IFM Therapeutics — IFM Therapeutics is a provider of small molecule that module novel targets in the innate immune system. The company and its academic collaborators combine unparalleled expertise in innate immunity with seasoned drug discovery and development professionals. Its subsidiary IFM Due is focused on the discovery and developing antagonists of thecGAS/STING pathway for the treatment of inflammation, neuroinflammation, autoimmunity and cancer. IFM Discovery, a newly financed incubator entity within the IFM enterprise, is prosecuting a basket of genetically-validated targets as next-generation therapies for inflammation, neuroinflammation, autoimmunity and fibrosis
Callio Therapeutics — Callio Therapeutics focuses on developing next-generation, multi-payload antibody-drug conjugates to maximize therapeutic benefits.
Scorpion Therapeutics — We are developing drugs specifically designed to interact with validated cancer targets with greater selectivity and optimized pharmaceutical properties to improve their safety and efficacy.

Engineering solutions to complex problems in health through venture investment and company creation.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Seed
United States, United Kingdom, China

Portfolio highlights

PetMedix — PetMedix develops next-generation antibody therapies for pets, using advanced biotechnology to create safer, more effective treatments for animal health.
Scout Bio — Scout Bio is a biotechnology company that specializes in veterinary, animal health, and gene therapy. The company is driven by its mission is to harness the genetic revolution transforming human medicine to deliver the future of veterinary medicine. Scout Bio was founded in 2016 and headquartered in Pennsylvania, United States.
Scratch — Scratch Financial is the nation's largest provider of simple, pet-friendly payment plans for veterinary care. Scratch Financial partners with veterinary clinics and provides pet owners with simple, friendly payment plans. Pet owners can apply, review, and accept a scratchpay.com payment plan in 90 seconds.

Investors by industry

Community

Artificial intelligence